By the Doktorly editorial team · Medically reviewed by the Doktorly medical team · Last updated: 30 October 2026
While the newer weight-loss injections rely on weekly doses, treatment with Saxenda works differently: the injection is used daily. For some that is a drawback – for others it is exactly the right balance of control and quick adjustability.
Here you will learn how Saxenda works, how the titration runs and for whom the daily variant is worthwhile.
Saxenda contains liraglutide at a dose of 3 mg and in 2015 became the first GLP-1 medication at all to be approved for weight reduction in the EU. The manufacturer is Novo Nordisk – the same group behind Ozempic and Wegovy. Technically, liraglutide is the "little brother" of semaglutide: shorter-acting, but faster to adjust.
The injection is given once daily – ideally at the same time of day, independent of meals. The dose increases stepwise over several weeks:
If the 3 mg dose is not tolerated, the medical team can decide on a permanently lower dose or discontinuation of treatment.
In the pivotal SCALE trial, participants on liraglutide 3 mg lost on average about 8 % of their body weight over 56 weeks – placebo: about 2.6 %. The Lancet: SCALE (2015). That is clearly less than with semaglutide or tirzepatide, but liraglutide has the longest practical track record among the weight-loss injections.
As a self-payer, treatment costs about 330–400 € per month. Because it is injected daily, more pen content is consumed than with weekly injections – though the cost spread between doses is smaller than one might expect.
Saxenda is worth considering if you prefer smaller, finely adjustable dose steps or experienced strong fluctuations with weekly injections. For adolescents aged 12 and over there is, in special cases, an approval path with specialists. Those seeking maximum efficacy will rather look at Wegovy or Mounjaro – the full comparison is here: weight-loss injections compared.
It depends on you. Daily dosing allows finer adjustment and faster tapering; weekly means fewer injections. Medically both routes are valid, though studies show higher weight-loss rates for the newer weekly agents.
On average about 8 % of starting weight after one year in trials. Individual results can be higher or lower.
Yes, for adolescents aged 12 and over with obesity – but treatment must be supervised by specialists and follows its own dosing recommendations.
Both contain liraglutide. Saxenda (3 mg daily) is approved for weight management, Victoza (up to 1.8 mg) for type 2 diabetes.